Bulk Inquiry
PX 20350
- FXR agonist Cpd 22
Axon 2152
CAS:
1198085-23-2
Purity:
99%
- Soluble in DMSO
- MF: C28H22Cl2F3N3O4
- MW: 592.39
Description
Potent farnesoid X receptor (FXR) agonist with enhanced affinity and efficacy (12 nM and 109% (compared to GW 4064)) in FXR FRET assay and full length FXR direct reporter (DR) assay (6 nM vs 30 nM for GW 4064). Cpd 22 showed a linear dose-dependent reduction in total plasma triglycerides and total plasma cholesterol.
More Information
| Parent CAS No. | 1198085-23-2 |
|---|---|
| Chemical Name | 4-(((6-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl)methoxy)-2-(trifluoromethyl)pyridin-3-yl)(methyl)amino)methyl)benzoic acid |
| SMILES | C1(C(F)(F)F)N=C(OCC2=C(C3CC3)ON=C2C2C(Cl)=CC=CC=2Cl)C=CC=1N(C)CC1C=CC(C(=O)O)=CC=1 |
| MFCD | N.A. |
| InChi | InChI=1S/C28H22Cl2F3N3O4/c1-36(13-15-5-7-17(8-6-15)27(37)38)21-11-12-22(34-26(21)28(31,32)33)39-14-18-24(35-40-25(18)16-9-10-16)23-19(29)3-2-4-20(23)30/h2-8,11-12,16H,9-10,13-14H2,1H3,(H,37,38) |
| InChiKey | KNWXWQGSCZVUGX-UHFFFAOYSA-N |
| CID | 44476535 |
| Short Description | FXR agonist |
References
- U. Abel et al. Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists. Bioorg. Med. Chem. Lett. 2010, 20, 4911–4917.
- U. Deuschle et al. FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model. PLoS One. 2012, 7, e43044.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1266 | GW 3965 hydrochloride |
From $104.50 |
| 1749 | WAY 362450 |
From $137.50 |
| 1991 | WYE 672 |
From $132.00 |
| 2357 | LXR 623 |
From $104.50 |
| 2363 | GSK 2033 |
From $115.50 |
| 2561 | DY 268 |
From $132.00 |
| 2598 | SR 9243 |
From $93.50 |
| 2657 | MGL-3196 |
From $99.00 |
| 3174 | Obeticholic acid |
From $77.00 |
| 4256 | Fexaramine |
From $137.50 |
Other Categories
Get a Quote for
Loading...